HEREDITARY BREAST CANCER: CURRENT STATE OF PROBLEM
Keywords:
hereditary breast cancer, BRCA1/2, mutations, screening, prevention, surgical interventionAbstract
Summary. The work is devoted to the actual problem
of oncology — hereditary breast cancer (BC). The
analysis and generalization of data of scientific literature on hereditary forms of BC, their prevalence,
genetic features, in particular, the frequency of mutations in the genes of BRCA1/2 in this form of pathology
(in Ukraine and in the world) has been carried out. Information on the current state of surveillance of healthy
women — carriers of BRCA1/2 gene mutations (associated with hereditary forms of cancer), principles
of preventive measures for the occurrence of hereditary BC that should increase the efficacy of prevention of BC in healthy carriers of gene mutations, improvement of long-term treatment results patients and,
in general, a better understanding of the proper management of such patients at all stages.
References
National Cancer Registry of Ukraine. Bulletins of 2000–
years (http://www.ncru.inf.ua/publications/index.htm)
(in Ukrainian).
Cancer in Ukraine, 2010–2011. Morbidity, Mortality, Indicators of the Oncology Service Activity. Bull Natl Cancer Register
Ukr. Kyiv, 2012; (13): 46–7 (in Ukrainian).
Cancer in Ukraine, 2015–2016. Morbidity, Mortality, Indicators of the Oncology Service Activity. Bull Natl Cancer Register Ukr. Kyiv, 2017; (18): 48–9 (in Ukrainian).
The Champalimaud Breast Unit (http://centroclinico.
fchampalimaud.org/en/oncology/breast-unit/).
Narod SA. Bilateral breast cancers. Nat Rev Clin Oncol
; 11 (3): 157–66.
Hahnen E, Lederer B, Hauke J, et al. Germline Mutation
Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSecondary Analysis of the
GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3 (10):
–85.
Da Silva L, Lakhani SR. Pathology of hereditary breast cancer. Mod Pathol 2010; 23 (2): 46–51.
Filippini SE, Vega A. Breast cancer genes: beyond BRCA1 and
BRCA2. Front Biosci 2013; 18: 1358–72.
Forsberg LA, Rasi C, Pekar G, et al. Signatures of post-zygotic structural genetic aberrations in the cells of histologically
normal breast tissue that can predispose to sporadic breast cancer.
Genome Res 2015; 25 (10): 1521–35.
Boroday NV, Datsyuk IO, Lukianova NY, et al. Hereditary
breast cancer: clinical, morphological and immunohistochemical
features. Onkologiia 2007; 9 (2): 105–9.
Paliychuk OV, Polyshchuk LZ, Rossokha ZI, Chekhun VF.
Investigation of ESR1 gene polymorphisms in patients with cancer of the female reproductive system with a burdened family history. Onkologiya 2016; 21: 316–24 (in Ukrainian).
Nielsen FC, van Overeem Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways.
Nat Rev Cancer 2016; 16 (9): 599–612.
Pruthi S, Gostout BS, Lindor NM. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc 2010; 85
(12): 1111–20.
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations
in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast
cancer. J Clin Oncol 2015; 33 (4): 304–11.
Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of
Patients With Breast Cancer. J Clin Oncol 2016; 34 (13): 1460–8.
Domagala P, Jakubowska A, Jaworska-Bieniek K, et al.
Prevalence of Germline Mutations in Genes Engaged in DNA
Damage Repair by Homologous Recombination in Patients with
Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers. PLoS ONE 2015; 10 (6): e0130393 (https://doi.org/10.1371/
journal.pone.0130393).
Breast Cancer NCCN Guidelines Vers. 2.2017.
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4 (9): 665–76.
Senkus E, Kyriakides S, Ohno S, et al. Primary Breast
Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2015;
(5): 8–30.
Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA
working group. Eur J Cancer 2010; 46: 1296–316.
Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N
Engl J Med 2017; 377 (6): 523–33.
Rennert G, Bisland-Naggan S, Barnett-Griness O, et al.
Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and
BRCA2 Mutations. N Engl J Med 2007; 357 (2): 115–23.
Li X, You R, Wang X, et al. Effectiveness of Prophylactic
Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis
and Systematic Review. Clin Cancer Res 2016; 22 (15): 3971–81.
Kostiuchenko Y, Motuzyuk I, Sydorchuk O. BRCA-associated breast cancer patients management. Przeglad Lekarski
; 74 (1): 77.
Motuzyuk I, Sydorchuk O, Kostiuchenko Y. Surgery treatment tactics in breast cancer patients with BRCA 1 and BRCA 2
mutations. Klin Onkol 2016; 4 (24): 87 (in Ukrainian).
Kostiuchenko Y, Zakharchuk S. Hereditary breast and ovarian cancer management. Orvos-Kepzes 2017; XCII: 38.
Motuzyuk I, Sydorchuk O, Kovtun N, Kostiuchenko Y. Synchronous and metachronous breast cancer in Ukraine. Ann Oncol 2017; 28 (5) (https://doi.org/10.1093/annonc/mdx364.007).
Motuzyuk I, Sydorchuk O, Kovtun N, Kostiuchenko Y. Synchronous and metachronous breast cancer in Ukraine. Breast Dis
; 37 (2): 83–93.
Motuzyuk I, Sydorchuk O, Kovtun N, et al. Analysis of
Trends and Factors in Breast Multiple Primary Malignant Neoplasms. Breast Cancer: Basic and Clinical Research, 2018, 12: 1–9.
doi: 10.1177/1178223418759959
